First new Front-Line treatment option for Hepatocellular Carcinoma (HCC).
First Tyrosine Kinase Inhibitor (TKI) for locally recurrent or metastatic, progressive RAI-refractory Differentiated Thyroid Cancer (DTC).
Lenvatinib plus everolimus is the first and only FDA-approved regimen for advanced Renal Cell Cancer (RCC) treatment.
Lenvanix is an oral capsule preparation which
is available in the strengths of 10 mg & 4 mg.
To know more visit our product website: www.lenvanix.com